Navigation Links
Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
Date:6/2/2008

o PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab currently is in a Phase II combination therapy trial for the treatment of advanced breast cancer and additional Phase II trials in non-small cell lung cancer (NSCLC) and breast cancer are expected to begin soon. A Phase I bavituximab monotherapy trial in advanced solid cancers is continuing.

Poster Number: 15G, Abstract No: 3038: R. Digumarti, P.P. Bapsy, J.S. Shan, "A phase Ib safety and pharmacokinetic study of bavituximab plus chemotherapy in patients with refractory advanced solid tumor malignancies." Sunday, June 1, 2008, 2:00 PM - 6:00 PM CDT.

Separately, on Saturday, May 31, 2008 Peregrine issued a press release reporting on its brain cancer drug Cotara(R). The release reviewed dosimetry trial data presented at ASCO confirming a key attribute of Cotara--that it specifically concentrates in brain tumors, leaving healthy tissue in the body largely unaffected. The release also reported that all of the GBM patients treated to date in the Cotara Phase II safety and efficacy trial have survived past the expected median survival time for relapsed GBM patients, an early but encouraging result. The press release can be found at http://ir.peregrineinc.com/releases.cfm

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides deve
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
2. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
3. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
9. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
10. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
11. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... antibody-drug conjugates for cancer, today announced the appointment of Thomas ... Reynolds has over 20 years, development experience gained in the ... Genetics. "I am delighted to welcome Tom at ...
(Date:1/15/2014)... More than 5 million Americans are currently living ... will die with Alzheimer’s or another dementia, according to ... many Americans into looking for ways to improve their ... cognitive disorders. Jonathan Weisman, president of Biohack Pure, is ...
(Date:1/15/2014)... 2014 2013 was a banner year ... Technologies®. They saw continued independent research led by the ... awarded a $1 million grant from the Susanne Marcus ... Behavior” a peer reviewed journal, Amy Grant highlighted Brainwave ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. – ... Warrington, Pa. , Details: The Hepatitis B Foundation, ... cure for hepatitis B and improving the quality of life ... on Friday, April 11 at Warrington Country Club in Warrington, ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... 2011 Sangui enters commercialization phase / Initial ... State of Tamaulipas has issued an initial order of Hemo2Spray, ... wound debridement product Scabremove both registered by the Mexican authorities ... order of the wound spray and Sangui management is positive ...
... and myeloma are both malignant diseases that arise from ... lymph nodes and the bone marrow. Although considerable progress ... they remain a significant challenge for patients and their ... for lymphoma and myeloma will be presented today at ...
... Corp. (NASDAQ: BSTC ), a biopharmaceutical company ... ® in the U.S. and XIAPEX ® ... George Gould, Esq., to its Board of Directors effective ... of George M. Gould, LLC, and of counsel to ...
Cached Biology Technology:Mexican State of Tamaulipas Starts Training Doctors in Sangui Wound Management 2Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 2Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 3Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 4Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 5Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 6Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 7Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 8Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 9BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 2BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 3BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 4
(Date:4/17/2014)... Luca Razzari of the nergie Matriaux Tlcommunications Research ... the John R. Evans Leaders Fund of the ... of state-of-the-art biotech and nanophotonics equipment. To this ... Ministre de l,Enseignement suprieur, de la Recherche, de ... new laboratories will help us develop new approaches ...
(Date:4/17/2014)... . Our eyes ... us with a continuous stream of information about our own ... in a car the world glides by us and ... effort, our brain calculates self-motion from this "optic flow". This ... gaze during our own movements. Together with biologists from the ...
(Date:4/17/2014)... Calif. One day about eight years ago, ... California, Riverside, and her father were on a field trip ... upon an orchid they had never seen before. , Unable ... on orchids. The orchid turned out to be an ... Lophiaris silverarum . , "Lophiaris" is the genus name, ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3
... than 200 million people worldwide and is a ... Osteoporosis Foundation. Resistance training often is recommended to ... (BMD), although previous studies that examined the effects ... Now, in a new study, University of Missouri ...
... cells tighten their belts: they start to digest their ... as autophagy - takes place in special organelles called ... have developed as a means of survival when times ... has become a kind of self-cleaning process. In mammalian ...
... team at the Centre for Stem Cell Research in Cambridge ... http://dev.biologists.org/ ) a new and safer way of generating pluripotent ... to every tissue of the body. Rapid developments in stem ... stem cell scientists to convert specialised cells, such as skin ...
Cached Biology News:Building strong bones: Running may provide more benefits than resistance training, MU study finds 2Self-digestion as a means of survival 2Researchers piggyback to safer reprogrammed stem cells 2
... The Jouan RC Maxi MB (for aqueous, ... vacuum concentrator/centrifugal evaporator systems respond to specific ... rapid and safe concentration of heat-labile samples. ... pumps, different of cold traps and a ...
... concentrator for efficient drying of small volumes ... system combines the SpeedVac™ Concentrator and chemically ... pump and rotor control, and dual timers ... time), makes the DNA120 indispensable in the ...
... Start up kit. Includes configured Laptop PC ... 1 MultiBlock satellite thermal Cycler (non-robotic). ... User friendly software. Store/track run data. ... lid. Outstanding uniformity. Advanced control ...
... Thermal Cycler is Thermo Electron's most advanced ... with easy to use sophisticated onboard software ... programming. Designed to offer performance, accuracy and ... a number of customer driven features built ...
Biology Products: